

## Special Issue

# Advances in Molecular Mechanisms of Head and Neck Cancers

### Message from the Guest Editors

Head and neck squamous cell carcinoma (HNSCC) ranks as the world's sixth most common cancer among male patients according to the GLOBOCAN 2020 database. The clinical outcomes for advanced-stage tumors remain unsatisfactory. Cisplatin, 5-FU and docetaxol are the most common chemotherapy agents for HNSCC; however, chemo-resistance is currently a major problem among patients with recurrent and metastatic disease (R/M disease). Checkpoint inhibitors can be applied for salvage in R/M disease according to the clinical trials Checkmate-141 and Keynote-048. Clinically, some patients demonstrate responses to checkpoint inhibitors, but a significant number of patients show progressive disease. There are several unique molecular features in these advanced, chemoresistant tumors, and some tumors are responsive to checkpoint inhibitors. For this Special Issue, we welcome submissions focusing on these molecular characters and highlighting new treatment strategies for HNSCC.

### Guest Editors

Prof. Dr. Chih-Yen Chien

1. Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
2. College of Medicine, Chang Gung University, Taoyuan City, Taiwan

Prof. Dr. Pei-Jen Lou

Department of Otolaryngology Head and Neck Surgery, National Taiwan University Hospital, Taipei, Taiwan

### Deadline for manuscript submissions

closed (30 September 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/157396](https://mdpi.com/si/157396)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).